Get the Stockscreener App
384.32
4.49%
16.52
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $384.32, with a volume of 3.84M.
It is up +4.49% in the last 24 hours and up +16.40% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$367.80
Open:
$369.99
24h Volume:
3.84M
Relative Volume:
1.31
Market Cap:
$207.15B
Revenue:
$36.71B
Net Income/Loss:
$7.71B
P/E Ratio:
27.01
EPS:
14.2284
Net Cash Flow:
$9.96B
1W Performance:
+12.41%
1M Performance:
+16.40%
6M Performance:
+35.01%
1Y Performance:
+29.06%
1-Day Range:
$368.90
$385.12
1-Week Range:
$338.59
$385.12
52-Week Range:
$261.43
$385.12
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
384.32 | 198.24B | 36.71B | 7.71B | 9.96B | 14.23 |
|
LLY
Lilly Eli Co
|
1,058.18 | 913.67B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
239.99 | 572.91B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.43 | 387.09B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
MRK
Merck Co Inc
|
121.93 | 297.22B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
AZN
Astrazeneca Plc
|
193.03 | 290.15B | 58.07B | 9.40B | 9.87B | 3.0115 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Kinsale Capital Group Inc. Has $9.65 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Bessemer Group Inc. Acquires 2,967 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock price hits 52-week high after Friday rally — what to watch into Monday - TechStock²
The Truth About Amgen Inc.: Is This Quiet Biotech Giant Your Next Power Move? - AD HOC NEWS
Amgen’s Stock Is Already Up 14% in 2026: Why Analysts Expect $440 - TIKR.com
Twin Capital Management Inc. Sells 5,541 Shares of Amgen Inc. $AMGN - MarketBeat
Renaissance Group LLC Lowers Position in Amgen Inc. $AMGN - MarketBeat
SBI Securities Co. Ltd. Has $977,000 Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
P/E Ratio Insights for Amgen - Benzinga
Amgen (AMGN) Sees Target Price Increase by Argus Research | AMGN Stock News - GuruFocus
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
Argus Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma - TipRanks
Amgen (AMGN) Target Price Raised by Guggenheim Analyst | AMGN St - GuruFocus
Amgen (NASDAQ:AMGN) Price Target Raised to $347.00 - MarketBeat
Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating - marketscreener.com
Amgen (NASDAQ:AMGN) Price Target Raised to $295.00 - MarketBeat
Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating - marketscreener.com
Aurdan Capital Management LLC Sells 5,316 Shares of Amgen Inc. $AMGN - MarketBeat
3,190 Shares in Amgen Inc. $AMGN Acquired by ABN AMRO Bank N.V. - MarketBeat
Biotechnology Market Set to Witness Significant Growth by 2026-2033 | Amgen Inc., GlaxoSmithKline - EIN News
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.
Cancer Supportive Care Drugs Market Is Going to Boom | Amgen Inc., - openPR.com
Amgen Refocuses Portfolio As Eczema Exit And Tavneos Review Raise Questions - Yahoo Finance
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5) - marketscreener.com
CVS Health to drop Amgen and Lilly’s bone disease treatments from some drug lists - WKZO
Key facts: Amgen's stock soars 8% on strong earnings; CVS to drop Prolia - tradingview.com
RBC Lifts Amgen (AMGN) Target After Strong Q4, Cites Key Drug Momentum - Finviz
CVS Health to swap Amgen and Lilly’s bone drugs with biosimilars in commercial formularies - Seeking Alpha
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists - Reuters
Amgen’s IMLYGIC Safety Study in Melanoma Reaches Completion: What Investors Should Watch - TipRanks
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Pfizer (PFE) and Merck & Company (MRK) - The Globe and Mail
Amgen Benefits From US Biosimilar Monopoly With $700m Sales For Pavblu - Citeline News & Insights
Why is Amgen stock falling premarket? - MSN
Why Is Amgen Stock Falling Premarket? - Stocktwits
BI Asset Management Fondsmaeglerselskab A S Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Jones Financial Companies Lllp Has $10.89 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Bank of America Maintains Underperform on Amgen Inc (AMGN) Feb 2026 - Meyka
Is It Time To Reassess Amgen (AMGN) After Strong Recent Share Price Gains - Yahoo Finance
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open - TechStock²
Amgen Earnings Call: Broad Growth Amid Manageable Risks - TipRanks
Amgen (AMGN) Surges on Q4 Earnings Beat, Leading Dow Gains - GuruFocus
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Asking Amgen to withdraw Tavneos, FDA revisits years-old data issue - BioCentury
Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal? - Finviz
Amgen Seen Driving Long-Term Growth on R&D Pipeline, Oppenheimer Says - marketscreener.com
Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus - TechStock²
Amgen climbs 8% after upbeat earnings report - breakingthenews.net
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
9.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):